BRPI0919155A2 - composição aquosa injetável - Google Patents

composição aquosa injetável

Info

Publication number
BRPI0919155A2
BRPI0919155A2 BRPI0919155A BRPI0919155A BRPI0919155A2 BR PI0919155 A2 BRPI0919155 A2 BR PI0919155A2 BR PI0919155 A BRPI0919155 A BR PI0919155A BR PI0919155 A BRPI0919155 A BR PI0919155A BR PI0919155 A2 BRPI0919155 A2 BR PI0919155A2
Authority
BR
Brazil
Prior art keywords
aqueous composition
injectable aqueous
injectable
composition
aqueous
Prior art date
Application number
BRPI0919155A
Other languages
English (en)
Inventor
Samuel Gavard Molliard
Original Assignee
Anteis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40342684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919155(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anteis Sa filed Critical Anteis Sa
Publication of BRPI0919155A2 publication Critical patent/BRPI0919155A2/pt
Publication of BRPI0919155B1 publication Critical patent/BRPI0919155B1/pt
Publication of BRPI0919155B8 publication Critical patent/BRPI0919155B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
BRPI0919155A 2008-11-07 2009-11-04 composição aquosa injetável BRPI0919155B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0857575A FR2938187B1 (fr) 2008-11-07 2008-11-07 Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
PCT/FR2009/052134 WO2010052430A2 (fr) 2008-11-07 2009-11-04 Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaïne, sterilisee a la chaleur

Publications (3)

Publication Number Publication Date
BRPI0919155A2 true BRPI0919155A2 (pt) 2015-12-08
BRPI0919155B1 BRPI0919155B1 (pt) 2019-12-10
BRPI0919155B8 BRPI0919155B8 (pt) 2021-05-25

Family

ID=40342684

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919155A BRPI0919155B8 (pt) 2008-11-07 2009-11-04 composição aquosa injetável

Country Status (13)

Country Link
US (1) US8455465B2 (pt)
EP (2) EP2676658B1 (pt)
JP (1) JP5626661B2 (pt)
KR (1) KR101514831B1 (pt)
CN (1) CN102196805B (pt)
BR (1) BRPI0919155B8 (pt)
CA (1) CA2742099C (pt)
DK (1) DK2676658T3 (pt)
ES (2) ES2443296T5 (pt)
FR (1) FR2938187B1 (pt)
PL (2) PL2349203T5 (pt)
RU (1) RU2493815C2 (pt)
WO (1) WO2010052430A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
EP2818184B1 (en) 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
WO2010028025A1 (en) 2008-09-02 2010-03-11 Gurtner Geoffrey C Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
FR2945949B1 (fr) * 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
EP2544652A2 (en) 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
EP3520827B1 (en) 2010-03-22 2022-05-25 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
IL206739A (en) 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
FR2963240B1 (fr) * 2010-07-28 2013-03-15 Horus Pharma Composition a usage topique sans conservateur comprenant de l'acide hyaluronique
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
IT1402382B1 (it) * 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico
FR2968996B1 (fr) * 2010-12-17 2013-04-12 Anteis Sa Formulation aqueuse injectable sterile utilisee en ophtalmologie
EP2484387A1 (en) * 2011-02-03 2012-08-08 Q-Med AB Hyaluronic acid composition
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
CN104853742B (zh) * 2012-10-08 2018-11-30 爱普蒂森股份公司 用于治疗用途的基于交联透明质酸和羟基磷灰石的可注射无菌水性制剂
BR112015007772B1 (pt) * 2012-10-08 2020-05-05 Anteis Sa formulação aquosa estéril injetável contendo ácido hialurônico reticulado e de hidroxiapatita para uso estético
US10463762B2 (en) 2012-10-08 2019-11-05 Anteis S.A. Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and hydroxyapatite for aesthetic use
US10434040B2 (en) 2012-10-08 2019-10-08 Anteis S.A. Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and hydroxyapatite for aesthetic use
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
LT3049055T (lt) * 2013-09-27 2018-07-25 Anteis S.A. Injekcinio hidrogelio, sterilizuoto karščiu, sudaryto iš hialurono rūgšties, turinčio miltelių pavidalo lidokaino ir šarminio agento, gamybos būdas
KR101459070B1 (ko) * 2013-12-09 2014-11-17 (주) 뉴메딕 지속성을 갖는 히알루론산 겔 조성물
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
AR099900A1 (es) 2014-04-01 2016-08-24 Merz Pharma Gmbh & Co Kgaa Rellenos para tejidos blandos con polisacáridos con persistencia mejorada, kit, procedimiento, uso
US20170035678A1 (en) 2014-04-17 2017-02-09 Merz Pharma Gmbh & Co. Kgaa Composition for improving the appearance of ageing skin
EP3200838B1 (en) 2014-09-30 2019-09-18 Allergan Industrie, SAS Stable hydrogel compositions including additives
TWI716365B (zh) * 2014-11-13 2021-01-21 德商梅茲製藥有限兩合公司 注射型真皮填充劑組合物及其套組、製備方法、與使用
FR3029928B1 (fr) 2014-12-15 2018-03-09 Teoxane Gel reticule
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2016128550A1 (en) 2015-02-13 2016-08-18 Allergan Industrie, Sas Implants for sculpting, augmenting or correcting facial features such as the chin
FR3036035B1 (fr) * 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
KR101855878B1 (ko) * 2015-07-24 2018-05-10 한양대학교 산학협력단 진피 필러용 하이드로젤 조성물
WO2017053339A1 (en) 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
FR3044557B1 (fr) * 2015-12-07 2017-12-01 Benedicte Vincente Gavard Molliard Tauzin Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
CN106074213A (zh) * 2016-06-24 2016-11-09 上海建华精细生物制品有限公司 用于水光注射的透明质酸钠凝胶及其制备方法和应用
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
KR20190051434A (ko) 2017-11-07 2019-05-15 주식회사 엑소코바이오 신규한 히알루론산 기반의 필러 조성물 및 이의 응용
CN110721341A (zh) * 2018-07-17 2020-01-24 上海美白臻生物科技有限公司 一种长效型玻尿酸制备工艺
US20210299335A1 (en) 2018-08-07 2021-09-30 Merz Pharma Gmbh & Co. Kgaa Method for dynamic filtration of a cross-linked hydrogel
WO2020111888A1 (ko) * 2018-11-30 2020-06-04 주식회사 엘지화학 히알루론산을 포함하는 활액보충재용 조성물
WO2020232539A1 (en) 2019-05-17 2020-11-26 The Governing Council Of The University Of Toronto Sustained release local anesthetic hydrogel composition
EP3854377A1 (fr) * 2020-01-22 2021-07-28 Laboratoires Genevrier Sas Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose
US11439537B2 (en) 2020-04-10 2022-09-13 Paul Phillips Opthalmic cannulated wound-stabilizing blade and method of using same
FR3111903B1 (fr) 2020-06-24 2022-12-02 Lab Vivacy Procede d’incorporation de composes organiques en solution au sein d’un hydrogel
WO2021259471A1 (en) * 2020-06-24 2021-12-30 Thor Dominik DERMAL FILLER WITH HIF-1α ACTIVITY MODULATORS
TWI751692B (zh) * 2020-09-11 2022-01-01 永立榮生醫股份有限公司 包括羊水幹細胞球之醫藥組合物及其治療尿失禁之用途
KR20220099922A (ko) * 2021-01-07 2022-07-14 주식회사 엘지화학 가교제 및 폴리올을 사용하여 가교된 가교 히알루론산 하이드로겔 및 이를 포함하는 필러
CN114712530B (zh) * 2022-04-18 2023-10-24 哈尔滨敷尔佳科技股份有限公司 提高重组胶原蛋白填充剂稳定性的湿热灭菌方法
KR102905855B1 (ko) * 2024-05-21 2025-12-30 부산대학교 산학협력단 필러 조성물 및 이를 이용한 필러 시술 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200080A1 (de) † 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
US7968110B2 (en) * 1992-02-11 2011-06-28 Merz Aesthetics, Inc. Tissue augmentation material and method
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US6284284B1 (en) * 1995-06-06 2001-09-04 Advanced Tissue Sciences, Inc. Compositions and methods for production and use of an injectable naturally secreted extracellular matrix
IT1303173B1 (it) 1998-07-15 2000-10-30 Mario Bo Macchina per la formatura di avvolgimenti per statori di macchinedinamo-elettriche e procedimento di formatura realizzato mediante
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
GB9902652D0 (en) 1999-02-05 1999-03-31 Fermentech Med Ltd Process
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
FR2850771B1 (fr) † 2003-02-04 2005-07-22 Intercreative Technologies Procede d'enrichissement du contenu d'une page numerique dont le format permet la creation de liens vers des objets informatiques
WO2004073759A1 (en) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
KR20070012306A (ko) 2003-07-30 2007-01-25 앙테이스 에스.아. 생의학적 사용을 위한 복합체 매트릭스
US8124120B2 (en) † 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US8524213B2 (en) 2003-12-30 2013-09-03 Genzyme Corporation Polymeric materials, their preparation and use
MXPA06007556A (es) * 2003-12-30 2006-08-31 Genzyme Corp Geles cohesivos de hialuronano y/o hilano entrecruzados, su preparacion y su uso.
SI1708722T1 (sl) * 2004-01-28 2014-10-30 The Regents Of The University Of California Nova intersticijska terapija za takojšnje simptome sprostitve in kronična terapija pri intersticijskem cistitisu
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20050281880A1 (en) 2004-05-20 2005-12-22 Wei Wang Methods for making injectable polymer hydrogels
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
WO2007041627A1 (en) * 2005-10-03 2007-04-12 Pinsky Mark A Compositions and methods for improved skin care
FR2895907B1 (fr) * 2006-01-06 2012-06-01 Anteis Sa Gel viscoelastique a usage dermatologique
US20070184087A1 (en) 2006-02-06 2007-08-09 Bioform Medical, Inc. Polysaccharide compositions for use in tissue augmentation
FR2900575B1 (fr) 2006-05-05 2008-10-17 Anteis Sa Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
FR2909560B1 (fr) * 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique
FR2924615B1 (fr) † 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2945949B1 (fr) † 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.

Also Published As

Publication number Publication date
FR2938187A1 (fr) 2010-05-14
WO2010052430A3 (fr) 2010-10-07
FR2938187B1 (fr) 2012-08-17
EP2676658B1 (fr) 2015-09-16
PL2349203T3 (pl) 2014-04-30
EP2349203A2 (fr) 2011-08-03
EP2349203B2 (fr) 2020-02-26
ES2443296T5 (es) 2020-10-29
BRPI0919155B8 (pt) 2021-05-25
ES2556475T3 (es) 2016-01-18
KR20110084510A (ko) 2011-07-25
EP2676658A1 (fr) 2013-12-25
KR101514831B1 (ko) 2015-04-24
BRPI0919155B1 (pt) 2019-12-10
WO2010052430A2 (fr) 2010-05-14
US20110201571A1 (en) 2011-08-18
PL2676658T3 (pl) 2016-07-29
CN102196805A (zh) 2011-09-21
PL2349203T5 (pl) 2021-02-08
CN102196805B (zh) 2013-10-16
JP5626661B2 (ja) 2014-11-19
ES2443296T3 (es) 2014-02-18
JP2012508217A (ja) 2012-04-05
DK2676658T3 (en) 2015-12-21
EP2349203B1 (fr) 2013-10-30
US8455465B2 (en) 2013-06-04
RU2493815C2 (ru) 2013-09-27
RU2011121426A (ru) 2012-12-10
CA2742099A1 (fr) 2010-05-14
CA2742099C (fr) 2017-08-08

Similar Documents

Publication Publication Date Title
NO2025013I1 (no) concizumab
BRPI0919155A2 (pt) composição aquosa injetável
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
EP2381760A4 (en) CORN PROTEIN COMPOSITION
DE602008002756D1 (de) Bauzusammensetzung
SMT201600307B (it) Composizione liposomiale
BRPI0917231A2 (pt) composição
DK2634232T3 (da) Sammensætninger
IT1392101B1 (it) Composizione comprendente isoflavoni
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI1013588A2 (pt) composição
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
DK3444343T3 (da) Polypeptider
BRPI1015474A2 (pt) composição
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DK2335031T3 (da) In-line-måler
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0907522A2 (pt) biarlamidas
EP2318641A4 (en) TOOL FOR CENTERING FOR DRILLING ENCLOSURE
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
DE602009000862D1 (de) Gehwagenbremse

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF